Chromosome 9p deletions are an independent predictor of tumor progression following nephrectomy in patients with localized clear cell renal cell carcinoma

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorOLIVEIRA, Daniel de
dc.contributor.authorDALL'OGLIO, Marcos F.
dc.contributor.authorREIS, Sabrina T.
dc.contributor.authorZERATI, Marcelo
dc.contributor.authorSOUZA, Isida C.
dc.contributor.authorLEITE, Katia R.
dc.contributor.authorSROUGI, Miguel
dc.date.accessioned2014-09-30T14:36:56Z
dc.date.available2014-09-30T14:36:56Z
dc.date.issued2014
dc.description.abstractObjectives: Chromosome 9p deletions have been observed in 14% to 36% of patients with clear cell renal cell carcinoma (ccRCC) and are associated with advanced-stage tumors. We evaluated whether chromosome 9p deletions are an independent predictor of worse outcomes in patients with localized ccRCC. Materials and methods: In this retrospective study, tumor samples from 94 patients with ccRCC NX-0 M0 who underwent radical nephrectomy or conservative renal surgery were analyzed using a fluorescence in situ hybridization technique. Results: The median follow-up period was 11.7 years, and 9p deletions were identified in 15% of cases. The cancer-specific survival rate estimated at 5 and 10 years was 99% and 96%, respectively, for patients without such chromosomal losses and 71% and 57% in patients with a loss of 9p (P < 0.001). Chromosome 9p deletions were an independent prognostic factor in a multivariate analysis, increasing the risk of death due to disease by 28-fold (95% CI: 5-155, P < 0.001). In patients with a low risk of progression, i.e., a low Stage, Size, Grade, and Necrosis score (0-2), low risk according to the University of California at Los Angeles Integrated Staging System, and low risk according to the pathological triad used at University of Sao Paulo, tumors with 9p deletions were significantly associated with a poorer cancer-specific survival at 10 years: 70%, 67%, and 67% vs. 98%, 97%, and 98%, respectively, in patients without 9p deletions. Conclusion: Chromosome 9p deletions independently establish a poorer prognosis for patients with localized ccRCC, providing further relevant clinical information that may improve the predictive ability of the main prognostic systems currently in use.
dc.description.indexMEDLINE
dc.identifier.citationUROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, v.32, n.5, p.601-606, 2014
dc.identifier.doi10.1016/j.urolonc.2013.12.008
dc.identifier.eissn1873-2496
dc.identifier.issn1078-1439
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/7328
dc.language.isoeng
dc.publisherELSEVIER SCIENCE INC
dc.relation.ispartofUrologic Oncology-Seminars and Original Investigations
dc.rightsrestrictedAccess
dc.rights.holderCopyright ELSEVIER SCIENCE INC
dc.subjectCarcinoma
dc.subjectRenal cell
dc.subjectChromosomes
dc.subjectHumans pair 9
dc.subjectChromosome deletion
dc.subjectPrognosis
dc.subjectIn situ hybridization
dc.subjectFluorescence
dc.subject.otherin-situ hybridization
dc.subject.othercancer
dc.subject.othersize
dc.subject.othertissue
dc.subject.othergrade
dc.subject.otherrisk
dc.subject.wosOncology
dc.subject.wosUrology & Nephrology
dc.titleChromosome 9p deletions are an independent predictor of tumor progression following nephrectomy in patients with localized clear cell renal cell carcinoma
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.author.externalZERATI, Marcelo:Univ Sao Paulo, Sch Med, Div Urol, Sao Paulo, Brazil
hcfmusp.author.externalSOUZA, Isida C.:Univ Sao Paulo, Sch Med, Div Urol, Sao Paulo, Brazil
hcfmusp.citation.scopus15
hcfmusp.contributor.author-fmusphcDANIEL DE OLIVEIRA GOMES
hcfmusp.contributor.author-fmusphcMARCOS FRANCISCO DALL'OGLIO
hcfmusp.contributor.author-fmusphcSABRINA THALITA DOS REIS FARIA
hcfmusp.contributor.author-fmusphcKATIA RAMOS MOREIRA LEITE
hcfmusp.contributor.author-fmusphcMIGUEL SROUGI
hcfmusp.description.beginpage601
hcfmusp.description.endpage606
hcfmusp.description.issue5
hcfmusp.description.volume32
hcfmusp.origemWOS
hcfmusp.origem.pubmed24629495
hcfmusp.origem.scopus2-s2.0-84902498391
hcfmusp.origem.wosWOS:000338090800013
hcfmusp.publisher.cityNEW YORK
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceBissig H, 1999, AM J PATHOL, V155, P267, DOI 10.1016/S0002-9440(10)65120-6
hcfmusp.relation.referenceBrunelli M, 2008, MODERN PATHOL, V21, P1, DOI 10.1038/modpathol.3800967
hcfmusp.relation.referenceCamp RL, 2000, LAB INVEST, V80, P1943, DOI 10.1038/labinvest.3780204
hcfmusp.relation.referenceChang LL, 2003, J UROLOGY, V170, P595, DOI 10.1097/01.ju.0000067626.37837.3e
hcfmusp.relation.referenceCordonCardo C, 1997, CANCER RES, V57, P1217
hcfmusp.relation.referenceDall'Oglio MF, 2007, J UROLOGY, V178, P425, DOI 10.1016/j.juro.2007.03.128
hcfmusp.relation.referenceFrank I, 2002, J UROLOGY, V168, P2395, DOI 10.1097/01.ju.0000035885.91935.d5
hcfmusp.relation.referenceGerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
hcfmusp.relation.referenceJones J, 2005, CLIN CANCER RES, V11, P5730, DOI 10.1158/1078-0432.CCR-04-2225
hcfmusp.relation.referenceKim HL, 2005, J UROLOGY, V173, P1496, DOI 10.1097/01.ju.0000154351.37249.f0
hcfmusp.relation.referenceKim SP, 2011, UROLOGY, V78, P1101, DOI 10.1016/j.urology.2011.05.012
hcfmusp.relation.referenceKinkle DA, 2007, J UROLOGY, V177, P849
hcfmusp.relation.referenceKlatte T, 2008, J UROLOGY, V179, P1719, DOI 10.1016/j.juro.2008.01.018
hcfmusp.relation.referenceKlatte T, 2009, J CLIN ONCOL, V27, P746, DOI 10.1200/JCO.2007.15.8345
hcfmusp.relation.referenceLa Rochelle J, 2010, CANCER-AM CANCER SOC, V116, P4696, DOI 10.1002/cncr.25279
hcfmusp.relation.referenceOzenne P, 2010, INT J CANCER, V127, P2239, DOI 10.1002/ijc.25511
hcfmusp.relation.referenceParker AS, 2009, CANCER, V115, P2092, DOI 10.1002/cncr.24263
hcfmusp.relation.referencePresti JC, 2002, J UROLOGY, V167, P1464, DOI 10.1016/S0022-5347(05)65346-3
hcfmusp.relation.referenceReid-Nicholson MD, 2011, ANN DIAGN PATHOL, V15, P37, DOI 10.1016/j.anndiagpath.2010.07.011
hcfmusp.relation.referenceSchullems D, 1997, J PATHOL, V183, P151
hcfmusp.relation.referenceSherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061
hcfmusp.relation.referenceSoung Sullivan Peggy, 2007, Curr Urol Rep, V8, P5
hcfmusp.relation.referenceVarella-Garcia M, 2006, DIAGN PATHOL, V1, DOI 10.1186/1746-1596-1-19
hcfmusp.relation.referenceZisman A, 2002, J CLIN ONCOL, V20, P4559, DOI 10.1200/JCO.2002.05.111
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublicationef0ac0f9-1795-4904-8094-810c5f3c4fa6
relation.isAuthorOfPublication0349f82a-1538-4caa-908f-f81634bd6256
relation.isAuthorOfPublication73be4bca-f8ad-443f-90b5-10e2e62b1e27
relation.isAuthorOfPublication23772d3b-0da7-472f-8d56-e6312dbf95c1
relation.isAuthorOfPublicationcff561dd-5732-4af5-abe9-538da0cdf4d2
relation.isAuthorOfPublication.latestForDiscoveryef0ac0f9-1795-4904-8094-810c5f3c4fa6
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_OLIVEIRA_Chromosome_9p_deletions_are_an_independent_predictor_of_2014.PDF
Tamanho:
308.5 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/55
Artigos e Materiais de Revistas Científicas - ODS/03